Table 2 Immunohistochemistry based molecular subtypes and pathological features for breast cancers diagnosed in Botswana between 2011 and 2015
|  | *ER/PR+/HER2- n (%) | ER/PR+/HER2+ n (%) | ER−/PR−/HER2 + HER2 enriched n (%) | ER−/PR−/HER2-Triple Negative n (%) |
|---|---|---|---|---|
| Â | 132 (62.6%) | 19 (9.0%) | 15 (7.1%) | 45 (21.3%) |
Histologic grade | ||||
 Grade 1 | 33 (25.0) | 5 (26.3) | 1 (6.7) | 2 (4.4) |
 Grade 2 | 59 (44.7) | 10 (52.6) | 8 (53.3) | 23 (51.1) |
 Grade 3 | 21 (15.9) | 3 (15.8) | 3 (20.0) | 13 (28.8) |
 Not specified/missing | 19 (14.4) | 1 (5.3) | 3 (20.0) | 7 (15.5) |
Age | ||||
  < 50 years | 50 (37.8) | 10 (52.6) | 5 (33.3) | 21 (46.7) |
  ≥ 50 years | 64 (48.5) | 6 (31.6) | 7 (46.7) | 19 (42.2) |
 Age not specified/missing | 18 (13.6) | 3 (15.8) | 3 (20.0) | 5 (11.1) |
Stage | ||||
 Stage I and Stage II | 5 (29.4) | 0 (0.0) | 0 (0.0) | 2 (28.6) |
 Stage III | 12 (70.6) | 1 (100.0) | 3 (100.0) | 5 (71.4) |